Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy
NCT07160634Phase 3Recruiting
- Sponsor
- Solid Biosciences
- Start
- Oct 2025
- Primary completion
- Jan 2029
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 3
01
Overview
A Phase 3 trial of SGT-003 in Duchenne muscular dystrophy (DMD), sponsored by Solid Biosciences. Started Oct 2025; status: recruiting.
02
Drugs
SGT-003
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07160634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07160634.